Major interaction on record — check this product against your medications before combining. Based on 5 of 9 ingredients. Check your meds →
Dietary supplement

Get Smart Ingredients & Drug Interactions

by Smart Nutrition

Get Smart label
See full label image
Capsule Category: Non-nutrient/non-botanical
Most serious interaction: Major
Clinical methodology reviewed by · Updated Sep 16, 2026 · Label data from the NIH DSLD
What is this page for?

First and foremost: checking Get Smart against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.

Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy

The interaction bottom line Most serious interaction: Major

Get Smart is a dietary supplement by Smart Nutrition with 9 active ingredients. Its ingredients are commonly taken for memory and cognitive support, alzheimer's disease and dementia, age-related memory decline.Based on those ingredients, 420 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Huperzine A, Vinpocetine, Piracetam. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

Jump to a section

Check Your Meds Against Get Smart by Smart Nutrition

Ask about any prescription or over-the-counter medication and we check it for interactions with Get Smart by Smart Nutrition — and tell you which ingredient is responsible.

Pharmacist-reviewed data Checks every ingredient Answer in seconds
Prefer a human? Send your question to our licensed pharmacists — free, answered by email within 24 hours.

HelloPharmacist Scorecard of Get Smart by Smart Nutrition

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

Generated from HelloPharmacist’s pharmacist-curated databases and editorial rules · Last generated Jul 11, 2026

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 9 of its 9 active ingredients.
  • No proprietary blends here — you can verify the dose of every single component.

Get Smart contains nine active ingredients aimed at cognition and brain function. Huperzine A is an acetylcholinesterase inhibitor (a compound that boosts a brain chemical called acetylcholine), while Vinpocetine, Idebenone, Piracetam, Oxiracetam, Aniracetam, Picamilon, Centrophenoxine, and Pyritinol each work through different mechanisms on brain metabolism and blood flow.

The product contains no inactive fillers or other ingredients — it is capsule form only.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: raise IQ and brain cognitive function.
  • We looked for evidence on: Age-related cognitive decline, Alzheimer disease, Attention deficit-hyperactivity disorder (ADHD), Cognitive impairment, Dementia, Dyslexia — and 4 related terms.
  • The strongest evidence on file: Vinpocetine is rated "Possibly Effective" for Dementia (Natural Medicines).
  • Also on file: Huperzine A is rated "Possibly Effective" for Alzheimer disease.
  • Also on file: Idebenone is rated "Possibly Effective" for Alzheimer disease.

The evidence for these ingredients varies. Huperzine A is possibly effective for Alzheimer disease but the data are insufficient for memory, cognitive impairment, vascular dementia, depression, and athletic performance.

Vinpocetine is possibly effective for dementia but insufficient evidence exists for tinnitus, motion sickness, stroke, and chronic fatigue syndrome. Idebenone is possibly effective for Alzheimer disease, muscular dystrophy, and Leber hereditary optic neuropathy, but possibly ineffective for Friedreich ataxia.

Piracetam is possibly effective for tardive dyskinesia, breath-holding attacks, vertigo, epilepsy, coronary artery bypass surgery recovery, and dyslexia. Picamilon and the ingredients we could not check lack established evidence in our data.

The evidence, ingredient by ingredient Huperzine A Vinpocetine Idebenone Picamilon Piracetam

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 4 of the 5 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 5 of 5.
  • General safety write-ups exist for 5 of 5.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Orally, huperzine A and idebenone are generally well tolerated, though huperzine A can cause dose-dependent cholinergic side effects — blurred vision, constipation, diarrhea, dizziness, dry mouth, insomnia, nausea, sweating, and vomiting. It may also lower heart rate.

Vinpocetine is well tolerated short-term but long-term safety is uncertain; reported side effects include anxiety, dizziness, headache, flushing, gastric discomfort, sleep disturbances, and rarely arrhythmias or seizures. Piracetam is generally well tolerated but can cause constipation, gastrointestinal upset, hypertension, rash, weight gain, and less commonly dizziness, drowsiness, agitation, anxiety, and sleep disturbance.

Idebenone is well tolerated; rare side effects include nausea, vomiting, abdominal pain, and loose stools. Pregnancy and breastfeeding safety data are insufficient or advise against use for huperzine A, vinpocetine, idebenone, picamilon, and piracetam — talk with your doctor or pharmacist for personalized guidance.

Side effects, ingredient by ingredient Huperzine A Vinpocetine Idebenone Picamilon Piracetam

Meds to double-check

Major interaction found
Known Interaction Concern · database check
Major identified

At least one ingredient has a documented Major-severity interaction. Check your medications for a personalized result.

Why this rating?
  • 4 of the 5 matched ingredients can interact with medications — Vinpocetine, Huperzine A, Picamilon, Piracetam.
  • The most serious interaction on file is rated Major.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs.
  • For scale: 420 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking Get Smart, check if you're on blood thinners or antiplatelet drugs (Major risk), anticholinergic or cholinergic medications (Moderate risk), CYP2C9-metabolized drugs (Moderate risk), or niacin (Moderate risk). These are the medication types documented to interact with ingredients in this product.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with some supporting evidence for its stated purpose. Major medication interactions have been identified, and safety information is well characterized.

Get Smart targets cognition with multiple active compounds, some with evidence (particularly huperzine A and vinpocetam for dementia) and others with limited data. If you take blood thinners, antiplatelet drugs, anticholinergic medications, cholinergic drugs, niacin, or drugs metabolized by CYP2C9, you need to check your exact medications before starting — the interaction potential is real and ranges from minor to major.

Talk to your pharmacist before adding this to your routine.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 5 of 9 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Oct 1, 2012.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Get Smart, straight from the product label.

Brand Smart Nutrition
Net contents 60 Cap(s)
Market status On market
Date entered into DSLD Oct 1, 2012
DSLD ID 13336
Product type Non-nutrient/non-botanical
Supplement form Capsule
Dietary claims / uses No Claim
Intended target group(s) Adult (18 - 50 Years)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Get Smart by Smart Nutrition, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
2 Capsule(s)
Maximum serving Sizes:
2 Capsule(s)
IngredientAmount% DV
Huperzine A100 mcg--
Vinpocetine10 mg--
Aniracetam800 mg--
Idebenone10 mg--
Picamilon100 mg--
Centrophenoxine300 mg--
Pyritinol300 mg--
Piracetam100 mg--
Oxiracetam10 mg--

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Brand IP Statement(s)

Get Smart(TM) brain formula Raise your IQ

FDA Statement of Identity

DIETARY SUPPLEMENT

General Statements

Pyritinol has been used in Europe since 1961 for various cognitive conditions such as dementia, head injury, stroke aftermath, coma, and cerebral circulatory disorders. Pyritinol has shown to help Attention Deficit Disorder (ADD) and is used by people of all ages to improve memory, concentration, and to enhance information processing. Picamilon is a Russian nootropic that enhances cerebral circulation. Picamilon is used in Russia to treat anxiety, depression, headaches, glaucoma, and eye disorders. Centrophenoxine raises brain acetylcholine levels thereby increasing alertness and attention span and improving learning ability. Aniracetam and Oxiracetam are nootropics that improve communication between the two brain hemispheres. Idebenone increases Nerve Growth Factor (NGF) in the brain. Idebenone has been used to treat Alzheimer's disease and to lessen brain damage from strokes. Idebenone protects the brain from excitotoxins like MSG and aspartame. Huperzine A (Huperzia serrata) is an ingredient found in Chinese Moss that enhances mental functioning by prolonging the life of the brain neurotransmitter acetylcholine. It works by inhibiting acetylcholinesterase, the enzyme that breaks down acetylcholine. This is the same mechanism of action by which the prescription drug Aricept works. Vinpocetine is a periwinkle plant extract that: 1. dilates the arteries of the brain but does no dilate other blood vessels 2. improves the brain's utilization of glucose. 3. improves vision for some 4. improves impaired hearing 5. improves Tinnitus (ringing in the ears) and Vertigo (dizziness). 6. can prevent stroke and mitigate damages in the aftermath of stroke.

Is this label outdated? Report a formula or label change and our pharmacy team will review it.

See for yourself

Get Smart by Smart Nutrition label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

Get Smart label

Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.

View the full label (PDF)
What’s inside

The Ingredients in Get Smart by Smart Nutrition

These are the 9 active ingredients this product is made of. Select any to open its full monograph.

Serving size2 Capsule(s) Dosage formCapsule Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Huperzine A

Interacts with
219 drugs
100 mcg per serving

Huperzine A is a purified compound from a Chinese clubmoss that acts like a mild cholinesterase inhibitor, similar in mechanism to some prescription A...

Huperzine A monograph & interactions

Vinpocetine

Interacts with
208 drugs
10 mg per serving

Vinpocetine is a lab-made compound based on a chemical from the periwinkle plant, and it is marketed mainly for memory and brain health. The evidence...

Vinpocetine monograph & interactions

Aniracetam

800 mg per serving

Idebenone

No known
interactions
10 mg per serving

Idebenone is a synthetic, lab-made antioxidant related to coenzyme Q10. It has been studied mostly as a prescription drug for certain rare mitochondri...

Idebenone monograph & interactions

Picamilon

Interacts with
3 drugs
100 mg per serving

Picamilon is a synthetic compound made by joining niacin (vitamin B3) and GABA, originally developed in the former Soviet Union as a prescription drug...

Picamilon monograph & interactions

Centrophenoxine

300 mg per serving

Pyritinol

300 mg per serving

Piracetam

Interacts with
122 drugs
100 mg per serving

Piracetam is a synthetic 'nootropic' drug studied mainly for cognitive decline, myoclonus, and certain neurological conditions, but evidence for boost...

Piracetam monograph & interactions

Oxiracetam

10 mg per serving
Interaction report

Get Smart by Smart Nutrition Drug Interactions

Want to check YOUR meds against Get Smart?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

 Go to the checker
420Drugs
122 Major 298 Moderate

Ingredients driving the most interactions

Huperzine A 219
Vinpocetine 208
Piracetam 122
Picamilon 3

Individual Drug Interactions

The ingredients in Get Smart interact with 420 drugs. Click any drug to see the details.

4 of the 9 ingredients in Get Smart interact with drugs. Each result below shows which ingredient is responsible. Huperzine A Vinpocetine Piracetam Picamilon

Each ingredient & the kinds of drugs it affects

For each ingredient in Get Smart with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Huperzine A2 drug types · 219 drugs

Anticholinergic Drugs

Theoretically, huperzine A might decrease the effects of anticholinergic drugs.
Huperzine A has acetylcholinesterase (AChE) inhibiting effects. In animal models, huperzine A reversed cognitive deficits induced by scopolamine, an anticholinergic drug.

Likelihood Possible Evidence D
Cholinergic Drugs

Theoretically, concurrent use of huperzine A with cholinergic drugs might increase the effects and side effects of these medications.
Huperzine A can inhibit acetylcholinesterase (AChE) and might cause cumulative effects if used with cholinergic drugs.

Likelihood Possible Evidence B
Huperzine A full monograph & interactions

Vinpocetine3 drug types · 208 drugs

Anticoagulant/Antiplatelet Drugs

Vinpocetine might increase the risk of bleeding when taken with anticoagulant or antiplatelet drugs.
Clinical research shows that vinpocetine decreases red blood cell aggregation, as well as plasma and whole blood viscosity. This effect has been seen with intravenous vinpocetine 1 mg/kg and oral vinpocetine 30 mg daily. Vinpocetine also seems to have antiplatelet effects.

Likelihood Possible Evidence B
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, vinpocetine might increase levels of drugs metabolized by CYP2C9.
In vitro research shows that vinpocetine weakly inhibits CYP2C9. However, this effect has not been reported in humans.

Likelihood Possible Evidence D
Warfarin (Coumadin)

Vinpocetine might modestly increase the risk of bleeding when taken with warfarin.
Clinical research shows that the combination of warfarin and vinpocetine leads to slight increases in prothrombin time and the area under the concentration curve for warfarin. However, these increases were small, and researchers suggest that this interaction is not likely to be clinically significant in most patients.

Likelihood Possible Evidence B
Vinpocetine full monograph & interactions

Piracetam1 drug type · 122 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, concomitant use of piracetam and anticoagulant/antiplatelet drugs might increase the risk of bleeding.
Preliminary clinical research shows that a single dose of piracetam inhibits platelet aggregation.

Likelihood Probable Evidence B
Piracetam full monograph & interactions

Picamilon1 drug type · 3 drugs

Niacin

Picamilon is broken down into gamma-aminobutyric acid (GABA) and niacin after oral administration. Concomitant use with niacin might cause additive effects and adverse effects. However, this interaction is only theoretical and has not been documented in humans.

Likelihood Possible Evidence D
Picamilon full monograph & interactions
The maker

Brand information

Manufacturer and brand details for Get Smart, from the product label.

Smart Nutrition

See all Smart Nutrition products
Name
Smart Nutrition
Pharmacist Counseling Corner

Get Smart by Smart Nutrition: Common Questions

Does Get Smart by Smart Nutrition interact with any medications?
Yes. Based on its ingredients, Get Smart has a known interaction with 420 medications, including 122 rated major. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Get Smart contains 9 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is Get Smart safe to take during pregnancy or while breastfeeding?
The safety data advise against use during pregnancy for huperzine A, vinpocetine, idebenone, picamilon, and piracetam. For breastfeeding, safety is either unknown or inadequate for all ingredients. Talk with your doctor or pharmacist before taking this if you're pregnant, planning to become pregnant, or breastfeeding.
What does huperzine A actually do?
Huperzine A blocks an enzyme that breaks down acetylcholine, a brain chemical involved in memory and thinking. It's possibly effective for Alzheimer disease, but the evidence for general memory or cognitive problems isn't clear yet.
Can Get Smart help with memory?
Huperzine A and vinpocetine are both possibly effective for dementia, and piracetam is possibly effective for several neurological conditions including epilepsy and vertigo. However, evidence for memory in otherwise healthy people is insufficient in our data.
What are the most common side effects I might notice?
Huperzine A can cause nausea, vomiting, diarrhea, dizziness, dry mouth, and blurred vision. Vinpocetine may cause anxiety, dizziness, headache, or sleep disturbances. Piracetam can cause constipation, gastrointestinal upset, and weight gain. These depend on dose and individual sensitivity.
Why does this product have so many different ingredients?
Each ingredient — huperzine A, vinpocetine, piracetam, idebenone, picamilon, and others — works through different mechanisms on brain metabolism, blood flow, or neurotransmitters. The idea is that together they may support cognition more broadly than any single one alone, though evidence for the combination as a whole isn't detailed in our data.
Is this product approved by the FDA?
No. Piracetam in particular is noted as unapproved in the U.S., and product quality across these nootropic ingredients is variable. This is a supplement, not a pharmaceutical medication, so regulatory oversight differs from prescription drugs.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Get Smart is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Get Smart label
Go deeper

The Full Monographs Behind Get Smart’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Huperzine A

Interacts with 219 drugs

Huperzine A is a purified compound from a Chinese clubmoss that acts like a mild cholinesterase inhibitor, similar in mechanism to some prescription Alzheimer's drugs. Some small studies sug...

Read the full Huperzine A monograph → Herb & supplement monograph

Vinpocetine

Interacts with 208 drugs

Vinpocetine is a lab-made compound based on a chemical from the periwinkle plant, and it is marketed mainly for memory and brain health. The evidence behind these uses is limited and not str...

Read the full Vinpocetine monograph → Herb & supplement monograph

Idebenone

Idebenone is a synthetic, lab-made antioxidant related to coenzyme Q10. It has been studied mostly as a prescription drug for certain rare mitochondrial and neurological conditions, and is a...

Read the full Idebenone monograph → Herb & supplement monograph

Picamilon

Interacts with 3 drugs

Picamilon is a synthetic compound made by joining niacin (vitamin B3) and GABA, originally developed in the former Soviet Union as a prescription drug. It is sold in some countries as a supp...

Read the full Picamilon monograph → Herb & supplement monograph

Piracetam

Interacts with 122 drugs

Piracetam is a synthetic 'nootropic' drug studied mainly for cognitive decline, myoclonus, and certain neurological conditions, but evidence for boosting memory in healthy people is weak. It...

Read the full Piracetam monograph →
Sources

Sources & How We Checked

Get Smart's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 84 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Huperzine A 13 references
  1. Skolnick AA. Old Chinese herbal medicine used for fever yields possible new Alzheimer Disease therapy. JAMA 1997;277:776. DOI
  2. Ye JW, Cai JX, Wang LM, Tang XC. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J Pharmacol Exp Ther 1999;288:814-9.. DOI
  3. Wang T, Tang XC. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol 1998;349:137-42. PubMed
  4. Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li Xue Bao 1995;16:391-5.
  5. Zhang RW, Tang XC, Han YY, et al. [Drug evaluation of huperzine A in the treatment of senile memory disorders]. Chung Kuo Yao Li Hsueh Pao 1991;12:250-2.
  6. Xu SS, Cai ZY, Qu ZW, et al. Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao 1999;20:486-90.
  7. Felgenhauer N, Zilker T, Worek F, Eyer P. Intoxication with huperzine A, a potent anticholinesterase found in the fir club moss. J Toxicol Clin Toxicol 2000;38:803-8.. PubMed
  8. Zhang, Z., Wang, X., Chen, Q., Shu, L., Wang, J., and Shan, G. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. Zhonghua Yi Xue Za Zhi 7-25-2002;82
  9. Cheng, D. H., Ren, H., and Tang, X. C. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 12-20-1996;8(1):97-101. PubMed
  10. Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. J Neural Transm (Vienna) 2009;116(4):457-65. PubMed
  11. Xu ZQ, Liang XM, Juan-Wu, Zhang YF, Zhu CX, Jiang XJ. Treatment with Huperzine A improves cognition in vascular dementia patients. Cell Biochem Biophys 2012;62(1):55-8. PubMed
  12. Yang G, Wang Y, Tian J, Liu JP. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One 2013;8(9):e74916. PubMed
  13. Xing SH, Zhu CX, Zhang R, An L. Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis. Evid Based Complement Alternat Med 2014;2014:363985. PubMed

See these in context on the Huperzine A monograph →

Vinpocetine 27 references
  1. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 1991;6:31-43. PubMed
  2. Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc 1987;35:425-30. PubMed
  3. Akopov SE, Gabrielian ES. Effects of aspirin, dipyridamole, nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination. Eur J Clin Pharmacol 1992;42:257-9. PubMed
  4. Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern Med Rev 1999;4:144-61..
  5. Wollschlaeger B. Efficacy of vinpocetine in the management of cognitive impairment and memory loss. JANA 2001;4:25-30.
  6. Hitzenberger G, Sommer W, Grandt R. Influence of vinpocetine on warfarin-induced inhibition of coagulation. Int J Clin Pharmacol Ther Toxicol 1990;28:323-8..
  7. Dekoninck, W. J., Jocquet, P., Jacquy, J., and Henriet, M. Comparative study of the clinical effects of vincamine + glycerol versus glycerol + placebo in the acute phase of stroke. Arzneimittelforschung. 1978;28(9):1654-1657.
  8. Fischhof, P. K., Moslinger-Gehmayr, R., Herrmann, W. M., Friedmann, A., and Russmann, D. L. Therapeutic efficacy of vincamine in dementia. Neuropsychobiology 1996;34(1):29-35. PubMed
  9. Feher, G., Koltai, K., Kesmarky, G., Horvath, B., Toth, K., Komoly, S., and Szapary, L. Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine. 2009;16(2-3):111-117. PubMed
  10. Kuzuya, F. Effects of vinpocetine on platelet aggregability and erythrocyte deformability. Ther Hung. 1985;33(1):22-34.
  11. Kovacs, L. Cavinton in the treatment of acute stroke. Ther Hung. 1985;33(1):50-57.
  12. Osawa, M. and Maruyama, S. Effects of TCV-3B (vinpocetine) on blood viscosity in ischemic cerebrovascular diseases. Ther.Hung. 1985;33(1):7-12.
  13. Ebi, O. Open-labeled phase III clinical trials with vinpocetine in Japan. Ther.Hung. 1985;33(1):41-49.
  14. Richichi, I., Valsecchi, O., Falcone, C., Sofi, A., and Zanini, L. [A case of "torsade de pointe" during vincamine therapy]. Minerva Cardioangiol. 1978;26(3):197-200.
  15. Dany, F., Merle, L., Goudoud, J. C., Liozon, F., Blanc, P., Bouvot, J. C., Nicot, G., and Dangoumau, J. [Cardiac toxicity of vincamine: a seven cases report of ventricular arrhythmias by parenteral administration of vincamine (author's transl)]. Therapie
  16. Fenzl, E., Apecechea, M., Schaltenbr, R., and Fridel, R. Long term study concerning tolerance and efficacy of vinpocetine in elderly patients suffering from a mild to moderate organic psychosyndrome. Senile dementia: early detection 1986;580-585.
  17. Peruzza, M. and DeJacobis, M. A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. ADV THER 1986;3(4):201-209.
  18. Manconi, E., Binaghi, F., and Pitzus, F. A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. CURR THER RES, CLIN EXP 1986;40(4):702-709.
  19. Blaha, L., Erzigkeit, H. L., Adamczyk, L. A., Freytag, L. S., and Schaltenbrand, R. Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Human Psychopharmacology: Clinical & Experimental 1989;4(2):103-111. DOI
  20. Shimizu, Y., Saitoh, K., Nakayama, M., Suto, K., Daikohara, R., and Nemoto, T. Agranulocytosis induced by vinpocetine. Medicine On-line 2011;
  21. Kong L, Song C, Ye L, et al. The Effect of Vinpocetine on Human Cytochrome P450 Isoenzymes by Using a Cocktail Method. Evid Based Complement Alternat Med. 2016;2016:5017135. PubMed
  22. Vinpocetine in Dietary Supplements. FDA Food/Dietary Supplements/Products & Ingredients. Available at: http://www.fda.gov/Food/DietarySupplements/ProductsIngredients/ucm518478.htm. Accessed 6 September 2016.
  23. Statement on warning for women of childbearing age about possible safety risks of dietary supplements containing vinpocetine. FDA Food/Dietary Supplements/Products & Ingredients. Available at: https://www.fda.gov/news-events/press-announcements/statement-
  24. Zhang W, Huang Y, Li Y, et al. Efficacy and safety of vinpocetine as part of treatment for acute cerebral infarction: A randomized, open-label, controlled, multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) trial. Clin Drug Investig 2016; PubMed
  25. National Toxicology Program. NTP technical report on the prenatal development toxicity studies of vinpocetine (CAS No. 42971-09-5) in Sprague Dawley Rats and New Zealand White Rabbits (Gavage Studies). Research Triangle Park, NC: National Toxicology Progr
  26. Gutiérrez-Farfán I, Reyes-Legorreta C, Solís-Olguín M, Alatorre-Miguel E, Verduzco-Mendoza A, Durand-Rivera A. Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: a phase II, open-label, single-center study. J Pharmacol Sci PubMed
  27. Hu X, Guo K, Li J, et al. Postoperative ecchymoma of eyelid after botulinum toxin injection for hemifacial spasm: a case report. Front Neurol 2023;14:1171303. PubMed

See these in context on the Vinpocetine monograph →

Idebenone 25 references
  1. Mariotti C, Solari A, Torta D, et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003;60:1676-9. PubMed
  2. Filla A, Moss AJ. Idebenone for treatment of Friedreich's ataxia? Neurology 2003;60:1569-70. PubMed
  3. Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 2002;87:346-9. PubMed
  4. Schols L, Vorgerd M, Schillings M, et al. Idebenone in patients with Friedreich ataxia. Neurosci Lett 2001;306:169-72. PubMed
  5. Lerman-Sagie T, Rustin P, Lev D, et al. Dramatic improvement in mitochondrial cardiomyopathy following treatment with idebenone. J Inherit Metab Dis 2001;24:28-34. PubMed
  6. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, et al. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 1999;354:477-9. PubMed
  7. Weyer G, Babej-Dolle RM, Hadler D, et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 1997;36:73-82. . PubMed
  8. Ikejiri Y, Mori E, Ishii K, et al. Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 1996;47:583-5. PubMed
  9. Pisano P, Durand A, Autret E, et al. Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy. Eur J Clin Pharmacol 1996;51:167-9. PubMed
  10. Ihara Y, Namba R, Kuroda S, et al. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. J Neurol Sci 1989;90:263-71. PubMed
  11. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J Neural Transm 1998;54:301-10. PubMed
  12. Di Prospero NA, Sumner CJ, Penzak SR, et al. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol 2007;64:803-8. PubMed
  13. Buyse GM, Voit T, Schara U, DELOS Study Group. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet. 2015;385(9979) PubMed
  14. Corben LA, Lynch D, Pandolfo M, Schulz JB, Delatycki MB; Clinical Management Guidelines Writing Group. Consensus clinical management guidelines for Friedreich ataxia. Orphanet J Rare Dis. 2014;9:184. DOI
  15. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007;6(10):878-86. PubMed
  16. Lagedrost SJ, Sutton MS, Cohen MS, et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J. 2011;161(3):639-645.e1. PubMed
  17. Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol. 2010;67(8):941-7. PubMed
  18. Mc Aleer MA, Collins P. Allergic contact dermatitis to hydroxydecyl ubiquinone (idebenone) following application of anti-ageing cosmetic cream. Contact Dermatitis. 2008;59(3):178-9. PubMed
  19. McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA 2nd, Maibach HI. Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone. J Cosmet Dermatol. 2005;4(3):167-73. PubMed
  20. Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol. 2012;25 PubMed
  21. Pineda M, Arpa J, Montero R, et al. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol. 2008;12(6):470-5. PubMed
  22. Catarino CB, von Livonius B, Priglinger C, et al. Real-world clinical experience with idebenone in the treatment of leber hereditary optic neuropathy. J Neuroophthalmol. 2020 Dec;40(4):558-565.
  23. Kosa P, Wu T, Phillips J, et al. Idebenone does not inhibit disability progression in primary progressive MS. Mult Scler Relat Disord. 2020 Oct;45:102434. PubMed
  24. Zhao X, Zhang Y, Lu L, Yang H. Therapeutic effects of idebenone on leber hereditary optic neuropathy. Curr Eye Res. 2020 Oct;45(10):1315-1323. PubMed
  25. Yuan LL, Chen TY, Huang ZQ. Effects of paroxetine hydrochloride combined with idebenone on inflammatory factors and antioxidant molecules in treatment of depression after ischemic stroke. Pak J Med Sci 2023;39(1):17-22. PubMed

See these in context on the Idebenone monograph →

Picamilon 3 references
  1. Avula B, Chittiboyina AG, Sagi S, et al. Identification and quantification of vinpocetine and picamilon in dietary supplements sold in the United States. Drug Test Anal. 2016;8(3-4):334-43. PubMed
  2. Vishnevskii EL, Guseva NB. Validation of the treatment of the neurogenic bladder in children with myelodysplasia using pikamilon [abstract only]. Urol Nefrol (Mosk) 1998;(2):27-30.
  3. Kolomoitseva EM, Ermakova VN, Abdulkadyrova MZh. Results of pikamilon use in the treatment of patients with open-angle glaucoma [abstract only]. Vestn Oftalmol 1994;110(4):4-7.

See these in context on the Picamilon monograph →

Piracetam 16 references
  1. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs 2010;70(3):287-312. PubMed
  2. Ozdemir H, Akinci E, Coskun F. Comparison of the effectiveness of intravenous piracetam and intravenous dimenhydrinate in the treatment of acute peripheral vertigo in the emergency department. Singapore Med J 2013;54(11):649-52. PubMed
  3. Kampman K, Majewska MD, Tourian K, et al. A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence. Addict Behav 2003;28(3):437-48. PubMed
  4. Koskiniemi M, Van Vleymen B, Hakamies L, et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Ne PubMed
  5. Fedi M, Reutens D, Dubeau F, et al. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 2001;58(5):781-6. PubMed
  6. Wilsher CR, Bennett D, Chase CH, et al. Piracetam and dyslexia: effects on reading tests. J Clin Psychopharmacol 1987;7(4):230-7. DOI
  7. Di Ianni M, Wilsher CR, Blank MS, et al. The effects of piracetam in children with dyslexia. J Clin Psychopharmacol. 1985;5(5):272-8. PubMed
  8. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11(2):169-82. PubMed
  9. Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol. 2009;39(3):311-21. PubMed
  10. Moriau M, Crasborn L, Lavenne-Pardonge E, et al. Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects. Arzneimittelforschung. 1993;43(2):110-8.
  11. Rao MG, Holla B, Varambally S, et al. Piracetam treatment in patients with cognitive impairment. Gen Hosp Psychiatry. 2013;35(4):451.e5-6. PubMed
  12. Tuncer S, Sencan A, Aral M, Ayhan S. Piracetam-induced dysarthria: an unusual complication of antithrombotic prophylaxis after toe to finger transfer. J Reconstr Microsurg. 2011;27(9):575-6. PubMed
  13. Waters B, Resnick M, Simeon J, et al. An adverse reaction to piracetam in an hypothyroid 10 year old boy. Prog Neuropsychopharmacol. 1980;4(2):207-9. PubMed
  14. Sandyk R, Gillman MA. Piracetam causes confusion in a patient with temporal lobe epilepsy. J Am Geriatr Soc. 1985;33(4):305. PubMed
  15. Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon M. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology. 1993;43(2):301-5. PubMed
  16. Rosenhall U, Deberdt W, Friberg U, Kerr A, Oosterveld W. Piracetam in patients with chronic vertigo. Clin. Drug Invest. 1996;11(5):251-60. DOI

See these in context on the Piracetam monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring
Supplement interaction checker › Check any supplement or product against your medications Drug–drug interactions › Check two or more of your medications against each other Browse medications A–Z › Every drug we've checked against herbs & supplements NDC & pricing lookup › Find a drug’s NDCs, packaging and costs Ask a pharmacist › Free, personal answer from our licensed team